AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 12 min read$TEM

LEFKOFSKY ERIC P sold $9.6M of TEM (indirect holdings)

LEFKOFSKY ERIC P (CEO and Chairman) sold 166,250 indirectly-held shares of Tempus AI, Inc. (TEM) at an average of $57.48 ($55.38–$59.23, $9.56M total) across 10 trades on 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LEFKOFSKY ERIC P
Published Jul 1, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TEM
Neutral
medium confidence
Mentioned
$TEM
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The newest actionable element is the disclosed sale size (~166,250 shares; ~$9.56M) and the stated 10b5-1 pre-arranged plan, which frames the transaction as planned rather than opportunistic.

02

Market read

Newly filed insider-sale data can influence short-term sentiment, but 10b5-1 labeling typically limits interpretive weight.

03

What to watch

Traders may overreact to insider sales; the key is whether subsequent filings show sales outside the planned schedule or changes in total insider ownership trend.

Relevance 5/10Novelty 6/10Timing: after-hours/next-session read-through from a newly filed Form 4 (filed 2026-07-01)

Background

The article is an SEC Form 4 insider transaction disclosure for Tempus AI, Inc. (TEM) by CEO/Chairman Eric P. Lefkofsky, executed across multiple trades on 2026-06-29.

Company-level read

Ticker impact

$TEMNeutralMedium confidence
Context

Tempus AI CEO/Chairman Eric P. Lefkofsky sold ~$9.56M of TEM shares via a 10b5-1 plan on 2026-06-29 at $55.38–$59.23.

Expected impact

Likely limited, short-lived sentiment impact; watch for follow-through only if selling accelerates beyond planned cadence.

Evidence & confidence

The filing is primary-source and time-stamped, but it explicitly states a pre-arranged 10b5-1 plan, which typically dampens interpretation as new negative information.

Market effects

Sector

Minimal; this is company-specific insider transaction with no sector-wide catalyst.

Regional

Minimal; no broader macro or regional linkage in the filing details.

Global

Minimal; no international deal/regulatory action described.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may be routine liquidity management rather than a bearish signal.

Key entities

  • issuer
    Tempus AI, Inc.

    Subject of the Form 4 insider sale; CEO/Chairman Eric P. Lefkofsky sold shares under a 10b5-1 plan.

  • insider
    LEFKOFSKY ERIC P

    CEO and Chairman; sold 166,250 shares indirectly on 2026-06-29 at $55.38–$59.23 (weighted avg $57.482).

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEM insider trading history →

Related articles

OCT 26
$TEMMed

What Happens To Tempus AI Stock If Its Cash Burn Continues?

Tempus AI (TEM) expects positive free cash flow by year-end but had a $273M cash burn over the past year. With $816M in cash, the company's reserves could last about three years at current burn rates. Revenue grew 20% and 36% in diagnostics and data businesses, respectively. Management raised 2026 revenue guidance to $1.595B-$1.605B and issued $460M in convertible notes. The company plans to acquire Personalis, potentially using debt to fund the deal.

finance.yahoo.com2 min
OCT 26
$BMYMed

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions

Pathos AI has partnered with Bristol Myers Squibb (BMY) and Tempus (TEM) to advance AI-driven drug development for Alzheimer’s and other neurological conditions. Tempus will create a dataset from hundreds of thousands of patients, which Pathos will license for $55 million over five years. BMY leads Pathos's Series E financing and gains access to Pathos's AI platform, Pathos Foundry, for its R&D portfolio, with exclusive rights in neuroscience for three years.

biospace.com3 min
OCT 24
$BMYMed

Tempus Sets $55 Million Ceiling for Pathos Neurology Data Contract

Tempus AI signed a five-year neurology data deal with Pathos AI, potentially worth $55 million. Tempus will deliver up to 500,000 records, with Pathos paying $100 per record. Bristol Myers Squibb gains nonexclusive Foundry access and three-year exclusive rights for neuroscience development. Tempus also has a $137.5 million oncology deal with BMS, totaling $192.5 million if both deals reach full value.

econotimes.com2 min
OCT 23
$TEMMed

Tempus AI Gains 6% as Bristol Myers Squibb Licenses Oncology Data

Tempus AI shares rose 6% after Bristol Myers Squibb agreed to a multi-year deal to license its oncology data through 2031. Tempus's data and AI platform will support BMS's drug discovery and development. Data licensing is Tempus's most profitable segment, with 36% revenue growth in Q2. The financial terms of the deal were not disclosed.

finance.yahoo.com2 min